Ad-Hoc Release detail page

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, March 9, 2022

Spexis to present strategy update and full-year 2021 financial results on March 24, 2022

Spexis AG (SIX: SPEX) announced today that it will publish its full-year financial results for 2021 on March 24 at 7.30am CET.

Jeffrey D. Wager, M.D. (CEO & Chairman) and Hernan Levett (CFO) will host an earnings call at 2.30pm CET, together with Juergen Froehlich, M.D. (CMDO) and Stephan Wehselau (COO). To access the earnings call, please use the following details:

France: +33 (0)1 70 730 3 39
Germany: +49 (0)69 22222 5197
Italy: +39 02 3602 6066
Switzerland +41 (0)44 580 7279
United Kingdom +44 (0)330 165 4012
United States +1 646-828-8073

Event Title: Spexis AG - Strategy Update and 2021 Financial Results

Confirmation code: 4015509
The presentation will also be available via webcast: https://www.webcast-eqs.com/spexis20220324
Link for participants of the conference call (only slides, no audio, no delay): https://www.webcast-eqs.com/spexis20220324/no-audio

After the call, the presentation will be available via the above link.

For further information please contact:

About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor AG and EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For further information please visit: www.spexisbio.com.

Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.